Abstract:Objective To investigate the efficacy and safety of docetaxel chemotherapy combined with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer.Methods One hundred and ninety-two cases of metastatic hormone-sensitive prostate cancer in Renji Hospital between January 2015 and July 2016 were analyzed retrospectively.Patients' age was 39 to 90,the median age was 71 years.The median prostate-specific antigen (PSA) at diagnosis was 90.6ng/ml (4.1-2 556.0 ng/ml).One hundred and eighty were with bone metastasis and 12 were with distant lymphatic metastasis.Sixty-one of them received docetaxel chemotherapy plus ADT for 3 weeks,131 received hormonal treatment alone.The median age of combination therapy group was 67 years (39-80 years),that of single treatment group was 75 years (50-93 years) (P ＜ 0.001).The median PSA baseline of the two groups were 91.6 ng/ml (35.5-157.5ng/ml) and 89.1 ng/ml (59.6-191.0 ng/ml) (P =0.324).Gleason score of combination therapy group showed that 3 cases (4.9％) was 6,23 cases (37.7％) 7,35 cases (57.4％) ≥8.That of single treatment group showed that 17 cases (13.0％) 6,51 cases (38.9％) 7,63 cases (48.1％) ≥8.There was no statistic difference between the two groups (P =0.122).But there was statistic difference in the rate of T3 or T4 clinical stage in primary lesion,that of combination therapy group was 50.7％ (37/61) and 34.4％ (21/61),and that of single treatment group was 60.3％ (79/131) and 21.4％ (28/131) (P =0.011).Imaging showed local lymph node metastasis in the two groups (80.3％ vs.67.9％,P =0.005).As to physical condition,the combination therapy group showed a lower ECOG score than the single treatment group (P ＜ 0.001).All the patients' survival condition,PSA response rate and adverse events were analyzed.Results One hundred and ninety-two patients were regularly followedup.The median follow-up time was 23.3 (14.4-33.4) months.Median progression free survival time of combination therapy group and single treatment group were respectively 24.4 (7.5-31.3) months vs.17.5(3.0-30.7) months (P ＜ 0.001).There were 1 and 16 cases died in the two groups due to disease progression.During the treatment,the rate of PSA level less than 0.2 ng/ml was 29.5％ (18/61) vs.13.7％ (18/131) in combination therapy group and single treatment group.Regarding the tolerance of combination therapy group,the incidence rate of grade 3-4 neutropenia was 27.9％ (17/61).Skin and mucous membrane damaged in 24.6％ (15/61) patients,transaminase rised in 13.1％ (8/61) patients,and peripheral nerve toxicity occurred in 9.8％ (6/61) patients.There was no significant difference between the 2 groups in relevant events caused by ADT,gynecomastia (14.8％ vs.16.3％) and erectile dysfunction (100％ vs.100％).Most of them could be relieved by symptomatic treatment.Conclusions For metastatic hormone-sensitive prostate cancer,docetaxel combined with hormonal treatment showed longer progression free survival than ADT alone with adverse reactions acceptable.

Characteristics Of Chinese Patients With Advanced Prostate Cancer: A Muliticentre, Non-Interventional, Observational, Prospective, Registry Study Of Docetaxel.

A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China.

Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study.

Real-world Use of Docetaxel for Metastatic Castration-Resistant Prostate Cancer in China: Results from a Large Observational Study

A Multicenter, Randomized Clinical Trial Comparing The Three-Weekly Docetaxel Regimen Plus Prednisone Versus Mitoxantone Plus Prednisone For Chinese Patients With Metastatic Castration Refractory Prostate Cancer

Prognostic factors of overall survival for Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy

Docetaxel Chemotherapy Plus Androgen-Deprivation Therapy in High-Volume Disease Metastatic Hormone-Sensitive Prostate Cancer in Chinese Patients: an Efficacy and Safety Analysis

Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel Plus Prednisone

Trends in Treatment for Prostate Cancer in China: Preliminary Patterns of Care Study in a Single Institution

Treatment Patterns And Patient Profiles For Docetaxel-Based Adjuvant Chemotherapy In Early-Stage Breast Cancer In China: A Pooled Analysis Of Four Observational Studies.

Adjuvant Hormone Therapy after Radical Prostatectomy in High-Risk Localized and Locally Advanced Prostate Cancer: First Multicenter, Observational Study in China

Prognostic value of prostate-specific antigen doubling time for patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy

Prognosic Analysis of Chemotherapy for Patients with Castration Resistant Prostate Cancer

[Clinical Efficacy of Docetaxel Combined with Carboplatin in Patients with Metastatic Castration-Resistant Prostate Cancer].

Docetaxel Chemotherapy Combined with Androgen-Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: an Efficacy and Safety Analysis

Docetaxel Plus Prednisone Versus Mitoxantrone Plus Prednisone for Metastatic Hormone-Refractory Prostate Cancer in Chinese Patients: Experience of a Single Center

Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer.

Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies.

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.

PSA Time to Nadir As a Prognostic Factor of First-Line Docetaxel Treatment in Castration-Resistant Prostate Cancer: Multicenter Validation in Patients from the Chinese Prostate Cancer Consortium

Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.